Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Users joke about Goku from Dragon Ball Z and his receding hairline.

The user has been taking oral Finasteride and topical Essengen 6 Plus for hair loss and is experiencing increased depression. They plan to get bloodwork to check hormone levels and are seeking advice on which tests to include.

The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

A user's transformation due to their efforts in fighting hair loss, which was achieved without a hair transplant; the discussion includes advice about treatments such as minoxidil and finasteride.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

Exploring the potential of using verteporfin during hair transplants to minimize scarring and regenerate follicles, as well as discussing a possible standardized protocol for this treatment.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

The conversation discusses the potential availability of GT20029 for hair loss treatment, with one user noting promising Phase 1 results and inquiring about gray market access. Another user humorously suggests it will take 50 years to become available.

The conversation discusses hair regrowth using dissolvable microneedles loaded with rapamycin and epigallocatechin gallate nanoparticles. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

A user tried a Korean hair loss shampoo and treatment set, noting it improved scalp and hair quality but lacked ingredient details. Other users expressed skepticism about its effectiveness, suggesting it might not significantly impact hair loss.

Mixing RU58841 with cetosomal minoxidil is discussed due to scalp irritation from ethanol PG vehicles. A mixture of the two turned bright pink when left to dry.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

A 22-year-old female with AGA due to PCOS is using 5% minoxidil foam and 2mg finasteride daily, and is seeking advice on microneedling frequency and safety. Concerns about finasteride dosage and its effects on PCOS were discussed, with emphasis on trusting the prescribed treatment plan.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

Chinese company gets green light for Pyrilutamide Phase II trial for androgenetic alopecia. Androgen receptors downregulate in androgen deficient environments.

The conversation discusses treating male pattern baldness in a transgender woman using cyproterone acetate, finasteride, and biotin. The original poster shared their experience for others who might be in a similar situation.

The user discusses a galenic hair lotion containing progesterone, estradiol, cyproterone, hydrocortisone butyrate, and cetirizine pheniramine, which has effectively stopped their hair loss over two years. They are curious about the compatibility of finasteride with the lotion's components and note that their trichologist has successfully used minoxidil and finasteride in similar treatments for others.

The user is dissatisfied with their hair transplant results from Asli Tarcan, citing poor donor area management and insufficient graft density. They advise against opting for cheaper procedures and express hope for future hair cloning solutions.

User discusses using Verteporfin for hair regrowth after hair transplant. Replies mention successful follicle regrowth in studies and mice, questioning if it can be replicated in humans.

A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.

A person had a successful hair transplant in Turkey with 3200 grafts using FUE and DHI techniques, and is satisfied with the results after 9 months. They have been using finasteride for 7 years to maintain hair health.

A user who didn't respond well to minoxidil and finasteride is considering the role of IGF-1 in hair loss treatment effectiveness. They discuss the potential of using HGH to improve hair growth and other health issues, referencing several sources that suggest IGF-1 levels may influence hair loss and treatment response.

Minoxidil, PRP, low-level light therapy, stem cell therapy, mesotherapy, Acell, and microneedling are discussed as treatments for thickening fine hairs in NW5 hair loss sufferers. A hair transplant may be necessary for significant improvement.

The user is considering using P5P to reduce high prolactin levels and is questioning if oral minoxidil could be contributing to the issue. They are also debating whether to switch from oral to topical minoxidil.

The conversation is about the effectiveness and trustworthiness of Pyrilutamide hair loss treatment sold by Hairlisciously, with concerns about product purity and a request for alternative suppliers. No specific treatments were confirmed to be used by participants.

David Barreto shared that a London-based research group is conducting a 12-month trial for a new nutraceutical treatment for pattern hair loss, designed with Dr. Carlos Puig. The trial aims to provide robust data, with results expected in 1-2 years, potentially representing a significant advancement since finasteride’s introduction in 1997.

A user is using homemade topical spironolactone for androgenetic alopecia and is unsure about its effectiveness due to concurrent telogen shedding. They are seeking advice on others' experiences with homemade topical spironolactone.